The EUCLEAK side-channel vulnerability was also known as the "Yubikey cloning attack". The BSI re-certified updated products ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Sony’s new flagship A1 Mark II has officially been announced and will release in early December, The new camera is already listed on some retailer sites with pre orders likely arriving in the coming ...

Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following ...

As travelers prioritize sustainability in a post-pandemic world, Vietnamese resorts are adapting. One leader in this trend is ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...